X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Liquidia will be responsible for development, regulatory and commercial activities of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for treating PAH and pulmonary hypertension associated with interstitial lung disease, in North America.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: L606
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Pharmosa Biopharm
Deal Size: $225.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration June 28, 2023
Details:
Liquidia intends to use the proceeds to fund the potential launch of Yutrepia, an inhaled dry powder formulation of treprostinil, upon final regulatory approval by the U.S. FDA and to support the continued clinical development of Yutrepia.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Yutrepia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: HealthCare Royalty
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 09, 2023
Details:
YUTREPIA/Tyvaso (treprostinil) inhalation powder, is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device for the treatment of pulmonary arterial hypertension.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tyvaso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: United Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
YUTREPIA is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability in adult patients. Tentative approval indicates that YUTREPIA has met all regulatory standards required for approval.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Yutrepia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
LIQ861 (treprostinil) Inhalation Powder and act as platelet aggregation, which being evaluated for the treatment of patients with pulmonary arterial hypertension.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LIQ861
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2021
Details:
The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LIQ861
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LIQ861
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Through the acquisition, RareGen attains the right to to commercialize Liquidia’s lead product candidate in Pulmonary Arterial Hypertension (PAH), LIQ861, an inhalation dry powder formulation of treprostinil that is produced using Liquidia's PRINT® Technology.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LIQ861
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: RareGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
